These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 21470582)

  • 41. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.
    Yardley DA; Raefsky E; Castillo R; Lahiry A; Locicero R; Thompson D; Shastry M; Burris HA; Hainsworth JD
    Clin Breast Cancer; 2011 Oct; 11(5):297-305. PubMed ID: 21729666
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Docetaxel-induced nasal septal perforation.
    Tan TH; Stevenson B; Yip D
    Intern Med J; 2006 Jul; 36(7):471-2. PubMed ID: 16780459
    [No Abstract]   [Full Text] [Related]  

  • 43. Paclitaxel plus bevacizumab for metastatic breast cancer.
    Haines IE; Miklos GL
    N Engl J Med; 2008 Apr; 358(15):1637; author reply 1637-8. PubMed ID: 18403775
    [No Abstract]   [Full Text] [Related]  

  • 44. Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study.
    Cortes J; Di Cosimo S; Climent MA; Cortés-Funes H; Lluch A; Gascón P; Mayordomo JI; Gil M; Benavides M; Cirera L; Ojeda B; Rodríguez CA; Trigo JM; Vazquez J; Regueiro P; Dorado JF; Baselga J;
    Clin Cancer Res; 2009 Jan; 15(1):307-14. PubMed ID: 19118059
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?
    Richardson DL; Backes FJ; Hurt JD; Seamon LG; Copeland LJ; Fowler JM; Cohn DE; O'Malley DM
    Gynecol Oncol; 2010 Jul; 118(1):47-51. PubMed ID: 20382413
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nasal septal perforation enlargement related to topical ocular steroids.
    Chiang MY; Shah P
    Br J Clin Pharmacol; 2005 Dec; 60(6):664-5. PubMed ID: 16305593
    [No Abstract]   [Full Text] [Related]  

  • 47. Sarcoidosis of the nose: report of a case with nasal perforation.
    Patey O; Bonnieux P; Roucayrol AM; Lafaix C
    Sarcoidosis; 1990 Sep; 7(2):123-4. PubMed ID: 2255788
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Optimizing outcomes with bevacizumab by better targeting patients and tumors.
    DeMichele A; Fox KR
    Oncology (Williston Park); 2009 Apr; 23(4):339-40. PubMed ID: 19476263
    [No Abstract]   [Full Text] [Related]  

  • 49. Onartuzumab with or without bevacizumab in combination with weekly paclitaxel does not prolong QTc or adversely affect other ECG parameters in patients with locally recurrent or metastatic triple-negative breast cancer.
    Borin MT; Chen M; Mocci S; Rubets I; Chittenden J; Aldairy W; Stroh M
    Cancer Chemother Pharmacol; 2015 Feb; 75(2):401-10. PubMed ID: 25542267
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Weekly administration of paclitaxel in the treatment of metastatic breast cancer: from rational to practice].
    Campone M; Fumoleau P
    Bull Cancer; 2002 Mar; 89(3):275-82. PubMed ID: 11940467
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adverse events in bevacizumab and chemotherapy: patient management.
    Blowers E; Hall K
    Br J Nurs; 2009 Apr 9-22; 18(7):424-8. PubMed ID: 19373187
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [A case of stage IV breast cancer with long-term partial response treated with tri-weekly paclitaxel plus bevacizumab].
    Okamoto A; Nakatsukasa K; Fujita Y; Sugimoto R; Sakaguchi K; Taguchi T
    Gan To Kagaku Ryoho; 2015 Mar; 42(3):343-6. PubMed ID: 25812504
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation.
    Fountzilas G; Kourea HP; Bobos M; Televantou D; Kotoula V; Papadimitriou C; Papazisis KT; Timotheadou E; Efstratiou I; Koutras A; Pentheroudakis G; Christodoulou C; Aravantinos G; Miliaras D; Petraki K; Papandreou CN; Papakostas P; Bafaloukos D; Repana D; Razis E; Pectasides D; Dimopoulos AM
    Anticancer Res; 2011 Sep; 31(9):3007-18. PubMed ID: 21868552
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
    von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
    Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Effect of Herceptin combined with Taxol on patients with Her-2/neu overexpressing metastatic breast cancer].
    Luo RC; Li AM; Zhang JY; Liao WJ; Ji CY; Miao JX
    Zhonghua Zhong Liu Za Zhi; 2004 Jan; 26(1):52-4. PubMed ID: 15059359
    [TBL] [Abstract][Full Text] [Related]  

  • 56. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy.
    Burstein HJ; Chen YH; Parker LM; Savoie J; Younger J; Kuter I; Ryan PD; Garber JE; Chen H; Campos SM; Shulman LN; Harris LN; Gelman R; Winer EP
    Clin Cancer Res; 2008 Dec; 14(23):7871-7. PubMed ID: 19047116
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bevacizumab-associated osteonecrosis of the jaw.
    Greuter S; Schmid F; Ruhstaller T; Thuerlimann B
    Ann Oncol; 2008 Dec; 19(12):2091-2. PubMed ID: 18977851
    [No Abstract]   [Full Text] [Related]  

  • 58. Cardiotoxicity in patients treated with bevacizumab is potentially reversible.
    Hawkes EA; Okines AF; Plummer C; Cunningham D
    J Clin Oncol; 2011 Jun; 29(18):e560-2. PubMed ID: 21606423
    [No Abstract]   [Full Text] [Related]  

  • 59. [Perforation of the nasal septum due to sarcoidosis].
    Udovicki J; Milankov O
    Med Pregl; 1995; 48(1-2):51-3. PubMed ID: 8657060
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Efficacy of bevacizumab in combination with paclitaxel for metastatic breast cancer].
    Suzuki S; Sakurai K; Nagashima S; Hara Y; Amano S; Enomoto K; Makishima M
    Gan To Kagaku Ryoho; 2014 Oct; 41(10):1289-91. PubMed ID: 25335720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.